

# WEST VIRGINIA LEGISLATURE

2020 REGULAR SESSION

ENROLLED

Committee Substitute

for

**House Bill 4102**

BY DELEGATES ROHRBACH, KESSINGER, ROBINSON,  
WALKER, BARTLETT, ELLINGTON, HANNA, HORNBUCKLE,

D. KELLY, MANDT AND PUSHKIN

[Passed March 6, 2020; in effect from passage.]

FILED

2020 MAR 25 P 4 23

OFFICE OF THE CLERK  
LEGISLATIVE SERVICES

HB4102

# WEST VIRGINIA LEGISLATURE

2020 REGULAR SESSION

**ENROLLED**

**Committee Substitute**

**for**

**House Bill 4102**

BY DELEGATES ROHRBACH, KESSINGER, ROBINSON,  
WALKER, BARTLETT, ELLINGTON, HANNA, HORNBUCKLE,  
D. KELLY, MANDT AND PUSHKIN

[Passed March 6, 2020; in effect from passage.]

OFFICE OF THE CLERK  
LEGISLATIVE SERVICES  
STATE HOUSE

2020 MAR 25 PM 4:23

FILED

1 AN ACT to amend and reenact §16-46-3 and §16-46-6 of the Code of West Virginia, 1931, as  
2 amended; and to amend and reenact §60A-9-4 of said code, all relating to opioid  
3 antagonists; prescribing an opioid antagonist; possessing an opioid antagonist;  
4 dispensing an opioid antagonist; providing an opioid antagonist; collecting data related to  
5 an opioid antagonist; requiring certain reporting of an opioid antagonist; providing  
6 immunity; making technical changes.

*Be it enacted by the Legislature of West Virginia:*

## **CHAPTER 16. PUBLIC HEALTH.**

### **ARTICLE 46. ACCESS TO OPIOID ANTAGONISTS ACT.**

#### **§16-46-3. Licensed health care providers may prescribe opioid antagonists to initial responders and certain individuals; required educational materials; limited liability.**

1 (a) The following individuals may prescribe an opioid antagonist in the manner prescribed  
2 by this subsection:

3 (1) A licensed health care provider acting in good faith and exercising good reasonable  
4 care may directly or by standing order prescribe an opioid antagonist to:

5 (A) A person at risk of experiencing an opioid-related overdose; or

6 (B) A family member, friend, or other person in a position to assist a person at risk of  
7 experiencing an opioid-related overdose.

8 (2) A licensed health care provider acting in good faith and exercising reasonable care  
9 may directly or by standing order prescribe an opioid antagonist to any governmental or non-  
10 governmental organization, including a local health department, a law enforcement agency, or an  
11 organization that promotes scientifically proven ways of mitigating health risks associated with  
12 substance use disorders and other high risk behaviors, for the purpose of distributing, through its  
13 agents, the opioid antagonist, to:

14 (A) A person at risk of experiencing an opioid-related overdose or

15 (B) A family member, friend, or other person in a position to assist a person at risk of  
16 experiencing an opioid-related overdose.

17 (b) A pharmacist may dispense an opioid antagonist to a person or organization pursuant  
18 to a prescription issued in accordance with subsection (a) of this section.

19 (c)(1) A governmental or non-governmental organization, including a local health  
20 department, a law enforcement agency, or organization that promotes scientifically proven ways  
21 to mitigate health risks associated with substance use disorders and other high-risk behaviors  
22 may, through its trained agents, distribute an opioid antagonist obtained pursuant to a prescription  
23 issued in accordance with this section to:

24 (A) A person at risk of experiencing an opioid-related overdose or

25 (B) A family member, friend, or other person in a position to assist a person at risk of  
26 experiencing an opioid-related overdose.

27 (2) An organization, through its trained agents, shall include with any distribution of an  
28 opioid antagonist pursuant to this subsection required education including opioid-related  
29 overdose prevention and treatment programs and instruction on how to administer the opioid  
30 antagonist.

31 (d) A person who receives an opioid antagonist that was prescribed pursuant to subsection  
32 (a) or distributed pursuant to subsection (c) may administer an opioid antagonist to another person  
33 if:

34 (1) The person has a good faith belief that the other person is experiencing a drug-related  
35 overdose; and

36 (2) The person exercises reasonable care in administering the drug to another person.

37 (e) A person and organization acting in good faith under the provisions of this section are  
38 immune from civil or criminal liability.

39 (f) A person and organization may possess an opioid antagonist, regardless of whether  
40 the person or organization holds a prescription for the opioid antagonist.

**§16-46-6. Data collection and reporting requirements; training.**

1 (a) Beginning March 1, 2016, and annually after that the following reports shall be  
2 compiled:

3 (1) The Office of Emergency Medical Services shall collect data regarding each  
4 administration of an opioid antagonist by an initial responder. The Office of Emergency Medical  
5 Services shall report this information to the Legislative Oversight Commission on Health and  
6 Human Resources Accountability, Joint Committee on Health and the West Virginia Bureau for  
7 Behavioral Health and Health Facilities. The data collected and reported shall include:

8 (A) The number of training programs operating in an Office of Emergency Medical  
9 Services-designated training center;

10 (B) The number of individuals who received training to administer an opioid antagonist;

11 (C) The number of individuals who received an opioid antagonist administered by an initial  
12 responder;

13 (2) The distribution of an opioid antagonist by a governmental or non-governmental entity,  
14 granting institution, medical provider, or pharmacy whose software cannot automatically report to  
15 the West Virginia Controlled Substance Monitoring Program database must report to the West  
16 Virginia Office of Drug Control Policy on a monthly basis. Report must be generated and  
17 submitted by the 10th day of each month for the opioid antagonists dispensed or distributed in  
18 the previous month. The following information must be reported:

19 (A) The name and address of the entity dispensing or distributing the opioid antagonist;

20 (B) The name and national drug code for each formulation of opioid antagonist dispensed  
21 or distributed;

22 (C) The total quantity of each formulation of opioid antagonist dispensed or distributed.

23 (3) The West Virginia Board of Pharmacy shall query the West Virginia Controlled  
24 Substances Monitoring Program database to compile all data related to the dispensing of opioid  
25 antagonists and combine that data with any additional data maintained by the Board of Pharmacy

26 related to prescriptions for and distribution of opioid antagonists. The aggregate data shall be  
27 reported to the West Virginia Office of Drug Control Policy by the 10th day of each month. By  
28 February 1 and annually thereafter, the West Virginia Office of Drug Control Policy shall provide  
29 a report of this information, excluding any personally identifiable information, to the Legislative  
30 Oversight Commission on Health and Human Resources Accountability, Joint Committee on  
31 Health and the West Virginia Bureau for Behavioral Health and Health Facilities.

32 (b) To implement the provisions of this article, including establishing the standards for  
33 certification and approval of opioid overdose prevention and treatment training programs and  
34 protocols regarding a refusal to transport, the Office of Emergency Medical Services may  
35 promulgate emergency rules pursuant to the provisions of section fifteen, article three, chapter  
36 twenty-nine-a of this code and shall propose rules for legislative approval in accordance with the  
37 provisions of said article.

## **CHAPTER 60A. UNIFORM CONTROLLED SUBSTANCES ACT.**

### **ARTICLE 9. CONTROLLED SUBSTANCES MONITORING.**

#### **§60A-9-4. Required information.**

1 (a) The following individuals shall report the required information to the Controlled  
2 Substances Monitoring Program Database when:

3 (1) A medical services provider dispenses a controlled substance listed in Schedule II, III,  
4 IV, or V;

5 (2) A prescription for the controlled substance or opioid antagonist is filled by:

6 (A) A pharmacist or pharmacy in this state;

7 (B) A hospital, or other health care facility, for outpatient use; or

8 (C) A pharmacy or pharmacist licensed by the Board of Pharmacy, but situated outside  
9 this state for delivery to a person residing in this state; and

10 (3) A pharmacist or pharmacy sells an opioid antagonist.

11 (b) The above individuals shall in a manner prescribed by rules promulgated by the Board  
12 of Pharmacy pursuant to this article, report the following information, as applicable:

13 (1) The name, address, pharmacy prescription number, and Drug Enforcement  
14 Administration controlled substance registration number of the dispensing pharmacy or the  
15 dispensing physician or dentist;

16 (2) The full legal name, address, and birth date of the person for whom the prescription is  
17 written;

18 (3) The name, address, and Drug Enforcement Administration controlled substances  
19 registration number of the practitioner writing the prescription;

20 (4) The name and national drug code number of the Schedule II, III, IV, and V controlled  
21 substance or opioid antagonist dispensed;

22 (5) The quantity and dosage of the Schedule II, III, IV, and V controlled substance or opioid  
23 antagonist dispensed;

24 (6) The date the prescription was written and the date filled;

25 (7) The number of refills, if any, authorized by the prescription;

26 (8) If the prescription being dispensed is being picked up by someone other than the  
27 patient on behalf of the patient, information about the person picking up the prescription as set  
28 forth on the person's government-issued photo identification card shall be retained in either print  
29 or electronic form until such time as otherwise directed by rule promulgated by the Board of  
30 Pharmacy; and

31 (9) The source of payment for the controlled substance dispensed.

32 (c) Whenever a medical services provider treats a patient for an overdose that has  
33 occurred as a result of illicit or prescribed medication, the medical service provider shall report  
34 the full legal name, address, and birth date of the person who is being treated, including any  
35 known ancillary evidence of the overdose. The Board of Pharmacy shall coordinate with the

36 Division of Justice and Community Services and the Office of Drug Control Policy regarding the  
37 collection of overdose data.

38 (d) The Board of Pharmacy may prescribe by rule promulgated pursuant to this article the  
39 form to be used in prescribing a Schedule II, III, IV, and V substance or opioid antagonist if, in the  
40 determination of the Board of Pharmacy, the administration of the requirements of this section  
41 would be facilitated.


42 (e) Products regulated by the provisions of §60A-10-1 *et seq.* of this code shall be subject  
43 to reporting pursuant to the provisions of this article to the extent set forth in said article.

44 (f) Reporting required by this section is not required for a drug administered directly to a  
45 patient by a practitioner. Reporting is, however, required by this section for a drug dispensed to a  
46 patient by a practitioner. The quantity dispensed by a prescribing practitioner to his or her own  
47 patient may not exceed an amount adequate to treat the patient for a maximum of 72 hours with  
48 no greater than two 72-hour cycles dispensed in any 15-day period of time.

49 (g) The Board of Pharmacy shall notify a physician prescribing buprenorphine or  
50 buprenorphine/naloxone within 60 days of the availability of an abuse deterrent or a practitioner-  
51 administered form of buprenorphine or buprenorphine/naloxone if approved by the Food and Drug  
52 Administration as provided in FDA Guidance to Industry. Upon receipt of the notice, a physician  
53 may switch his or her patients using buprenorphine or buprenorphine/naloxone to the abuse  
54 deterrent or a practitioner-administered form of the drug




The Joint Committee on Enrolled Bills hereby certifies that the foregoing bill is correctly enrolled.


  
.....  
Chairman, House Committee


  
.....  
Chairman, Senate Committee

Originating in the House.

In effect from passage.

  
.....  
Clerk of the House of Delegates

  
.....  
Clerk of the Senate

  
.....  
Speaker of the House of Delegates


  
.....  
President of the Senate

OFFICE OF THE CLERK OF THE HOUSE OF DELEGATES

2020 MAR 25 PM 4:23

FILED

The within is approved this the 25th day of March, 2020.

  
.....  
Governor

PRESENTED TO THE GOVERNOR

MAR 19 2020

Time 11:27 am